硼替佐米
神经干细胞
神经发生
神经球
蛋白酶体抑制剂
免疫印迹
干细胞
蛋白酶体
生物
癌症研究
胚胎干细胞
分子生物学
细胞生物学
多发性骨髓瘤
免疫学
成体干细胞
生物化学
基因
作者
Seung Yeon Sohn,Hyun‐Jung Kim
摘要
Abstract Background Dysregulation of protein degradation is related with various diseases including Alzheimer’s disease. Bortezomib is the first drug to treat multiple myeloma, however, the major side effect is induction of peripheral neuropathy. This study was performed to explore the effects and mechanisms of proteasome inhibition in neural stem cells (NSCs). Method Cortical neural stem cells were obtained and cultured from embryonic day 14 rats. By immunocytochemistry (ICC), western blot analysis and real‐time PCR followed by reverse transcription PCR, the cell fate of neural stem cells were identified. Toxicity was determined by MTT assay and neurosphere size measurement. BCL2‐BAX protein ratio was detected by western blot to explore the cytotoxic mechanisms. Result Neurogenesis was significantly increased by bortezomib in proliferating NSCs when determine by ICC, western blot and PCR. However, such effect was not observed during NSC differentiation. In addition, Bortezomib induced toxicity in both proliferating NSCs and differentiated cells. Conclusion Bortezomib is toxic to NSCs and differentiated cells, however, it induced neurogenesis in NSCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI